Cryoablation Or Brachytherapy? Endocare Promotes Prostate First-Line Option
This article was originally published in The Gray Sheet
Executive Summary
Endocare is hoping that the results of an eight-year 590-patient registry study will convince more urologists to use cryoablation as an alternative to brachytherapy for first-line treatment of prostate cancer
You may also be interested in...
$35 Mil. Timm Medical Acquisition Broadens Endocare Urology Market
Endocare's Feb. 21 acquisition of Timm Medical Technolgies provides a much-enlarged customer base for its urology product offering
Endocare Cryocare
Minimally-invasive cryosurgical system gains 510(k) clearance for "keyhole" thoracoscopic cardiac tissue ablation procedures to treat arrhythmias. The clearance opens the door for "a new generation of devices currently under development that treat certain cardiac conditions in a less invasive fashion" under a September 2001 strategic alliance with CryoCath Technologies (1"The Gray Sheet" Oct. 1, 2001, p. 30)...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.